Trial Profile
A Phase II Trial Of IM862 [oglufanide] Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oglufanide (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 15 Sep 2005 New trial record.